Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30076591 | 1.00 | MCL1 (1.00) | MCL1PGRCYP2C9CYP2C19MEN1 | |
| SCHEMBL15055672 | 0.89 | MCL1 (0.80) | MCL1PGRCYP2C9CYP2C19FFAR1 | |
| SCHEMBL7828166 | 0.88 | MCL1 (0.78) | MCL1MEN1KMT2AALDH1A1PFKFB3 | |
| SCHEMBL9996888 | 0.87 | MCL1 (0.77) | MCL1PGRMEN1KMT2AALDH1A1 | |
| SCHEMBL9997215 | 0.85 | MCL1 (0.74) | MCL1MEN1KMT2AALDH1A1PFKFB3 | |
| SCHEMBL9996812 | 0.83 | ALDH1A1 (0.81) | MCL1PGRMEN1KMT2AALDH1A1 | |
| SCHEMBL9997330 | 0.82 | MCL1 (0.70) | MCL1MEN1KMT2AALDH1A1PFKFB3 | |
| SCHEMBL150434 | 0.81 | MCL1 (0.68) | MCL1MEN1KMT2AALDH1A1PFKFB3 | |
| SCHEMBL1130086 | 0.81 | MCL1 (0.68) | MCL1MEN1KMT2AALDH1A1PFKFB3 | |
| SCHEMBL9997075 | 0.81 | MCL1 (0.68) | MCL1MEN1KMT2AALDH1A1PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | claimed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | claimed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | UNIV MARYLAND (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3319938-B1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF | UNIV MARYLAND (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| US-10858316-B2 | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858316-B2 | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-08 | — | — | US | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| US-20180208554-A1 | Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 2018-07-26 | — | — | US | disclosed |
| US-20180208554-A1 | Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 2018-07-26 | — | — | US | disclosed |
| US-20180208554-A1 | Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 2018-07-26 | — | — | US | disclosed |
| WO-2017011323-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-01-19 | — | — | WO | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161201-A1 | BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | MCL1, TP53, MYC | MCL1 1/4885PGR 4485/4885CYP2C9 4854/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | MCL1 1411/4885PGR 3872/4885CYP2C9 3736/4885 |
| US-10858316-B2 | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof | MCL1, BCL3, BCL9 | MCL1 1/4885PGR 4485/4885CYP2C9 4851/4885 |
| US-20180208554-A1 | Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof | MCL1, BCL3, BCL9 | MCL1 1/4885PGR 4485/4885CYP2C9 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.